摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,6-二溴-3-羟基吡啶 | 6602-33-1

中文名称
2,6-二溴-3-羟基吡啶
中文别名
(1,1,4,4-四甲基-2-丁炔-1,4-二基)二叔丁基过氧化物
英文名称
2,6-dibromopyridin-3-ol
英文别名
2,6-dibromo-3-hydroxypyridine;2,6-Dibrom-3-hydroxy-pyridin
2,6-二溴-3-羟基吡啶化学式
CAS
6602-33-1
化学式
C5H3Br2NO
mdl
——
分子量
252.893
InChiKey
RKOLKIWJSXSHLV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    164.0 to 168.0 °C
  • 沸点:
    369.3±37.0 °C(Predicted)
  • 密度:
    2.228±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    33.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319
  • 储存条件:
    室温

SDS

SDS:7e5f8416d771149ce9b20033091d447d
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2,6-Dibromo-3-hydroxypyridine
Synonyms: 2,6-Dibromopyridin-3-ol

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Dibromo-3-hydroxypyridine
CAS number: 6602-33-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3Br2NO
Molecular weight: 252.9

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,6-二溴-3-羟基吡啶 在 [1,3-bis(diphenylphosphino)propane]nickel(II) dichloride 、 rhodium on alumina 盐酸正丁基锂magnesiumN-乙基异丙基胺1,2-二溴乙烷乙酰氯 作用下, 以 甲醇二氯甲烷 为溶剂, -78.0~25.0 ℃ 、9.0 MPa 条件下, 反应 13.08h, 生成 (+/-)-spicigerinate de methyle
    参考文献:
    名称:
    Hasseberg, Hans-Albrecht; Gerlach, Hans, Liebigs Annalen der Chemie, 1989, p. 255 - 262
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-羟基吡啶 、 sodium hydroxide 作用下, 反应 1.0h, 生成 2,6-二溴-3-羟基吡啶
    参考文献:
    名称:
    超分子催化剂中的轴向手性
    摘要:
    使用DFT计算设计了一种能够形成轴向手性超分子复合物的新型配体。两个手性的单体,每个设有一个共价结合的手性辅助剂,形成双齿膦与在协调与过渡金属中心的扭曲,氢键结合骨架配体导致两个非对映体,Tropos公司复合体。溶液中非对映异构体的比例非常依赖于温度和溶剂。铑和铂配合物是通过NMR研究,ESI-MS测量以及UV-VIS和圆二色光谱结合起来进行分析的。在铑催化的α-脱氢氨基酸的不对称氢化中评估了手性自组织配体,并获得了良好的转化率和高对映选择性。这项研究为通过立体定向手性中心对超分子组装体进行立体控制的新配体设计开辟了道路。
    DOI:
    10.1002/anie.201801048
点击查看最新优质反应信息

文献信息

  • 5-HT RECEPTOR MODULATORS
    申请人:Kapadnis Prashant Bhimrao
    公开号:US20130053372A1
    公开(公告)日:2013-02-28
    The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    本发明涉及式(I)化合物,用于治疗由5-羟基色胺(血清素)受体IB(5-HT1B)介导的疾病,例如血管疾病、癌症和CNS疾病。本发明还提供了治疗这些疾病的方法,以及用于治疗的化合物和组合物等。
  • [EN] 5-HT RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE LA 5-HT
    申请人:CAMBRIDGE ENTPR LTD
    公开号:WO2011098776A1
    公开(公告)日:2011-08-18
    The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
    这项发明涉及到式(I)的化合物,用于治疗通过5-羟色胺(血清素)受体IB(5-HT1B)介导的疾病,例如血管疾病、癌症和中枢神经系统疾病。该发明还提供了治疗这些疾病的方法,以及用于治疗的化合物和组合物等。
  • Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
    申请人:——
    公开号:US20030045540A1
    公开(公告)日:2003-03-06
    The invention provides compounds of Formula I: 1 where in W is 2 These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which &agr;7 is known to be involved.
    这项发明提供了Formula I的化合物: 其中W为 这些化合物可以是药用盐或组合物的形式,也可以是消旋混合物或其纯对映体。Formula I的化合物可用于治疗已知涉及α7的疾病或症状。
  • [EN] TYK-2 INHIBITOR<br/>[FR] INHIBITEUR DE TYK -2
    申请人:BEIGENE LTD
    公开号:WO2021259208A1
    公开(公告)日:2021-12-30
    Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.
    本发明公开了一种式I化合物,用于抑制TYK2并治疗与不良tyk-2活性相关的疾病(tyk-2相关疾病),使用本发明所述化合物治疗炎症或自身免疫疾病的方法,以及包含所述化合物的药物组合物。
  • Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists
    作者:Miguel Guerrero、Mariangela Urbano、Jian Zhao、Melissa Crisp、Peter Chase、Peter Hodder、Marie-Therese Schaeffer、Steven Brown、Hugh Rosen、Edward Roberts
    DOI:10.1016/j.bmcl.2011.10.096
    日期:2012.1
    potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure–activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1–3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility
    S1P 4受体 (S1P 4 -R) 的高亲和力和选择性小分子激动剂可能在包括自身免疫性疾病、病毒感染和血小板减少症在内的多种疾病领域具有重要的治疗效用。分子库-小分子库库的高通量筛选 (HTS) 鉴定出 3-(2-(2,4-dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine 是一种中等效力和选择性的 S1P 4 -R击中激动剂。HTS 衍生命中的设计、合成和系统的结构-活性关系研究导致了新型强效 S1P 4 -R 激动剂的开发,该激动剂对剩余的 S1P 1-3,5 具有极好的选择性-Rs 家庭成员。值得注意的是,本文报道的分子提供了新的药理学工具来破译生物学功能并评估 S1P 4 -R的治疗效用。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-